Finally! As of July 5, the CoxaTrain hip orthosis can be prescribed by name and with its medical aid number, and the claim submitted to the statutory health insurance provider. What is particularly noteworthy: the project team successfully managed not only the product launch challenges caused by the pandemic, but also unexpected obstacles during the allocation of the medical aid number by the German National Association of Statutory Health Insurance Funds. During the project completion meeting on June 8 in Zeulenroda, Germany, Chief Executive Officer Rainer Berthan honored this huge step in the key area of expertise that is osteoarthritis and congratulated the team on this achievement.
At the moment, there is no similar orthosis available on the market: the CoxaTrain mobilizes the hip joint in cases of osteoarthritis, rheumatoid arthritis, or hip impingement. It provides relief during walking, alleviates hip pain, and relaxes the muscles involved in movement. This helps delay endoprosthetic surgery for as long as possible.